JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matthews, R. T.
Right arrow Articles by Blair, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matthews, R. T.
Right arrow Articles by Blair, D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*DOPAMINE
*HALOPERIDOL

Effects of BMY 14802, a potential antipsychotic drug, on rat brain dopaminergic function

RT Matthews, BA McMillen, R Sallis and D Blair

The potential neuroleptic alpha-(4-fluorophenyl)-4-(5-fluoro-2- pyrimidinyl)-1-piperazine-butanol HCl (BMY 14802-1) was tested for its effects on mesotelencephalic dopamine (DA) neurons in albino rats. BMY 14802-1 increased DA turnover in DA terminal regions, increased nigral DA neuronal impulse flow and blocked the behavioral stimulation and inhibition of DA neuronal impulse flow caused by DA agonists. BMY 14802- 1 also increased tyrosine hydroxylase activity in vivo but did not directly affect tyrosine hydroxylase activity in vitro. In contrast to these findings, BMY 14802-1 did not cause catalepsy at any dose and reversed catalepsy produced by haloperidol. BMY 14802-1 did not block DA autoreceptors on either DA neuron soma/dendrites or on striatal nerve terminals, as assessed by inhibition of DA neuronal impulse flow by microiontophoresed DA and by inhibition of tyrosine hydroxylase activity by apomorphine, respectively. BMY 14802-1 had very low affinity for striatal D-2 receptors (IC50 greater than 10(-5) M) as determined by displacement of [3H]spiperone binding in vitro. Finally, BMY 14802-1 increased impulse flow of nigral DA neurons after pretreatment with haloperidol but had no effect on impulse flow when microiontophoresed directly onto DA neurons. It is concluded that BMY 14802-1 blocked DA-mediated effects in the mesostriatal and mesocortical/limbic systems through a non-DA receptor mechanism. BMY 14802-1 has potential as a neuroleptic with little indication of extrapyramidal motor effects.

Volume 239, Issue 1, pp. 124-131, 10/01/1986
Copyright © 1986 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
M. M. El-Mas, M. Fan, and A. A. Abdel-Rahman
Endotoxemia-Mediated Induction of Cardiac Inducible Nitric-Oxide Synthase Expression Accounts for the Hypotensive Effect of Ethanol in Female Rats
J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 368 - 375.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. A. Vanecek, W. D. Essman, D. P. Taylor, and J. H. Woods
Discriminative Stimulus Characteristics of BMY 14802 in the Pigeon
J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 1 - 9.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1986 by the American Society for Pharmacology and Experimental Therapeutics.